The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes (Q28273497)

PLASMA INSULIN RESPONSE TO ORAL AND INTRAVENOUS GLUCOSE ADMINISTRATION

Europe PubMed Central

title

The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes (English)

0 references

0 references

1

Daniel J Drucker

0 references

author name string

Michael A Nauck

series ordinal

2

0 references

language of work or name

English

0 references

publication date

11 November 2006

0 references

published in

The Lancet

0 references

volume

368

0 references

page(s)

1696-705

0 references

issue

9548

0 references

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969705-5

7 January 2021

Stimulation of insulin secretion by gastric inhibitory polypeptide in man

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969705-5

7 January 2021

Biological effects and metabolic rates of glucagonlike peptide-1 7-36 amide and glucagonlike peptide-1 7-37 in healthy subjects are indistinguishable

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969705-5

7 January 2021

Enhanced insulin secretion and improved glucose tolerance in mice lacking CD26.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969705-5

7 January 2021

Both Subcutaneously and Intravenously Administered Glucagon-Like Peptide I Are Rapidly Degraded From the NH2-Terminus in Type II Diabetic Patients and in Healthy Subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969705-5

7 January 2021

Glucagon-like peptide I stimulates insulin gene expression and increases cyclic AMP levels in a rat islet cell line

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969705-5

7 January 2021

The biology of incretin hormones

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969705-5

7 January 2021

Glucagon-like peptide-1 receptor signaling modulates beta cell apoptosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969705-5

7 January 2021

Glucagon-like peptide 1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969705-5

7 January 2021

Glucose competence of the hepatoportal vein sensor requires the presence of an activated glucagon-like peptide-1 receptor

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969705-5

7 January 2021

Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969705-5

7 January 2021

Glucose intolerance caused by a defect in the entero-insular axis: a study in gastric inhibitory polypeptide receptor knockout mice

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969705-5

7 January 2021

Glucose intolerance but normal satiety in mice with a null mutation in the glucagon-like peptide 1 receptor gene.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969705-5

7 January 2021

Exendin(9-39)amide is an antagonist of glucagon-like peptide-1(7-36)amide in humans

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969705-5

7 January 2021

Reduced incretin effect in type 2 (non-insulin-dependent) diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969705-5

7 January 2021

Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969705-5

7 January 2021

Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969705-5

7 January 2021

Determinants of the effectiveness of glucagon-like peptide-1 in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969705-5

7 January 2021

Glucagon-like peptide 1 and its derivatives in the treatment of diabetes.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969705-5

7 January 2021

Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969705-5

7 January 2021

Intravenous glucagon-like peptide 1 normalizes blood glucose after major surgery in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969705-5

7 January 2021

Blood glucose control in healthy subject and patients receiving intravenous glucose infusion or total parenteral nutrition using glucagon-like peptide 1.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969705-5

7 January 2021

Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969705-5

7 January 2021

Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969705-5

7 January 2021

Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969705-5

7 January 2021

Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969705-5

7 January 2021

Improved glycemic control with no weight increase in patients with type 2 diabetes after once-daily treatment with the long-acting glucagon-like peptide 1 analog liraglutide (NN2211): a 12-week, double-blind, randomized, controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969705-5

7 January 2021

Five weeks of treatment with the GLP-1 analogue liraglutide improves glycaemic control and lowers body weight in subjects with type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969705-5

7 January 2021

Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969705-5

7 January 2021

Twelve-week monotherapy with the DPP-4 inhibitor vildagliptin improves glycemic control in subjects with type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969705-5

7 January 2021

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969705-5

7 January 2021

Tissue-specific expression of unique mRNAs that encode proglucagon-derived peptides or exendin 4 in the lizard.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969705-5

7 January 2021

Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969705-5

7 January 2021

Bedtime administration of NN2211, a long-acting GLP-1 derivative, substantially reduces fasting and postprandial glycemia in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969705-5

7 January 2021

Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969705-5

7 January 2021

Differential effects of acute and extended infusions of glucagon-like peptide-1 on first- and second-phase insulin secretion in diabetic and nondiabetic humans

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969705-5

7 January 2021

Exenatide augments first- and second-phase insulin secretion in response to intravenous glucose in subjects with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969705-5

7 January 2021

Abnormal patterns of insulin secretion in non-insulin-dependent diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969705-5

7 January 2021

Near-normalisation of diurnal glucose concentrations by continuous administration of glucagon-like peptide-1 (GLP-1) in subjects with NIDDM.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969705-5

7 January 2021

Effect of intravenous infusion of exenatide (synthetic exendin-4) on glucose-dependent insulin secretion and counterregulation during hypoglycemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969705-5

7 January 2021

Exendin 4 controls insulin production in rat islet beta cells predominantly by potentiation of glucose-stimulated proinsulin biosynthesis at the translational level

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969705-5

7 January 2021

Cellular composition of the human diabetic pancreas

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969705-5

7 January 2021

Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969705-5

7 January 2021

Protein kinase Czeta activation mediates glucagon-like peptide-1-induced pancreatic beta-cell proliferation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969705-5

7 January 2021

Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969705-5

7 January 2021

The long-acting GLP-1 derivative NN2211 ameliorates glycemia and increases beta-cell mass in diabetic mice

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969705-5

7 January 2021

Chronic inhibition of dipeptidyl peptidase-4 with a sitagliptin analog preserves pancreatic beta-cell mass and function in a rodent model of type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969705-5

7 January 2021

Glucagon-like peptide-1 inhibits apoptosis of insulin-secreting cells via a cyclic 5'-adenosine monophosphate-dependent protein kinase A- and a phosphatidylinositol 3-kinase-dependent pathway

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969705-5

7 January 2021

beta-Cell Pdx1 expression is essential for the glucoregulatory, proliferative, and cytoprotective actions of glucagon-like peptide-1.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969705-5

7 January 2021

Dipeptidyl peptidase IV inhibitor treatment stimulates beta-cell survival and islet neogenesis in streptozotocin-induced diabetic rats.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969705-5

7 January 2021

Truncated GLP-1 (proglucagon 78-107-amide) inhibits gastric and pancreatic functions in man.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969705-5

7 January 2021

Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitus.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969705-5

7 January 2021

Weight gain as a risk factor for clinical diabetes mellitus in women.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969705-5

7 January 2021

Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969705-5

7 January 2021

Pharmacology of exenatide (synthetic exendin-4): a potential therapeutic for improved glycemic control of type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969705-5

7 January 2021

Effectiveness of progressive dose-escalation of exenatide (exendin-4) in reducing dose-limiting side effects in subjects with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969705-5

7 January 2021

Exenatide elicits sustained glycaemic control and progressive reduction of body weight in patients with type 2 diabetes inadequately controlled by sulphonylureas with or without metformin

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969705-5

7 January 2021

Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969705-5

7 January 2021

The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969705-5

7 January 2021

Pharmacokinetics, pharmacodynamics, safety, and tolerability of a single-dose of NN2211, a long-acting glucagon-like peptide 1 derivative, in healthy male subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969705-5

7 January 2021

Dose-response for glycaemic and metabolic changes 28 days after single injection of long-acting release exenatide in diabetic fatty Zucker rats

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969705-5

7 January 2021

Development and characterization of a glucagon-like peptide 1-albumin conjugate: the ability to activate the glucagon-like peptide 1 receptor in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969705-5

7 January 2021

A recombinant human glucagon-like peptide (GLP)-1-albumin protein (albugon) mimics peptidergic activation of GLP-1 receptor-dependent pathways coupled with satiety, gastrointestinal motility, and glucose homeostasis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969705-5

7 January 2021

Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969705-5

7 January 2021

Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969705-5

7 January 2021

Dipeptidyl-peptidase IV (CD26)--role in the inactivation of regulatory peptides

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969705-5

7 January 2021

Natural substrates of dipeptidyl peptidase IV.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969705-5

7 January 2021

Dipeptidyl peptidase IV substrates. An update on in vitro peptide hydrolysis by human DPPIV

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969705-5

7 January 2021

Therapeutic strategies based on glucagon-like peptide 1.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969705-5

7 January 2021

Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: results from two randomized, double-blind, placebo-controlled studies with single oral doses

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969705-5

7 January 2021

The therapeutic actions of DPP-IV inhibition are not mediated by glucagon-like peptide-1.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969705-5

7 January 2021

1-[[(3-hydroxy-1-adamantyl)amino]acetyl]-2-cyano-(S)-pyrrolidine: a potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycemic properties

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969705-5

7 January 2021

Improved meal-related beta-cell function and insulin sensitivity by the dipeptidyl peptidase-IV inhibitor vildagliptin in metformin-treated patients with type 2 diabetes over 1 year

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969705-5

7 January 2021

Discovery and preclinical profile of Saxagliptin (BMS-477118): a highly potent, long-acting, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969705-5

7 January 2021

Type 2 diabetes--therapy with dipeptidyl peptidase IV inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969705-5

7 January 2021

Dipeptidyl peptidase IV inhibition for the treatment of type 2 diabetes: potential importance of selectivity over dipeptidyl peptidases 8 and 9.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969705-5

7 January 2021

Normalization of glucose concentrations and deceleration of gastric emptying after solid meals during intravenous glucagon-like peptide 1 in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969705-5

7 January 2021

Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2806%2969705-5

7 January 2021

10.1016/S0140-6736(06)69705-5

Identifiers

DOI

1 reference

Consolidated OpenCitations Corpus – April 2017

25565

25565

1 reference

Consolidated OpenCitations Corpus – April 2017

Consolidated OpenCitations Corpus – April 2017

1 reference